Market overview
The global virus inactivation market is worth USD 935 mn in 2026 and is forecast to reach USD 2.4 bn by 2036, growing at a 10.0% CAGR. United States is the largest country market and Low pH hold is the largest by method segment.
| Scope | Viral inactivation products and services used in biologics manufacturing, including low pH, solvent-detergent, heat and UV-C treatment systems, reagents and viral clearance studies. |
|---|---|
| Industry | Healthcare |
| Value 2025 | USD 850 mn |
| Value 2026 | USD 935 mn |
| Value 2036 | USD 2.4 bn |
| CAGR 2026-2036 | 10.0% |
| Volume 2026 | 153 thousand units |
| Volume 2036 | 378 thousand units |
| Average price 2026 | USD 6,102 per unit |
| Report price | Starts from USD 1,999 |
| Published | November 2026 |
Request a free sample of this report
Virus Inactivation market size and forecast, 2026-2036
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Year | Market value |
|---|---|
| 2026 | USD 935 mn |
| 2027 | USD 1.0 bn |
| 2028 | USD 1.1 bn |
| 2029 | USD 1.2 bn |
| 2030 | USD 1.4 bn |
| 2031 | USD 1.5 bn |
| 2032 | USD 1.7 bn |
| 2033 | USD 1.8 bn |
| 2034 | USD 2.0 bn |
| 2035 | USD 2.2 bn |
| 2036 | USD 2.4 bn |
Virus Inactivation market segmentation
By method
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Low pH hold | 30.0% | 26.9% | USD 280 mn | 8.8% |
| Solvent and detergent | 24.0% | 20.6% | USD 224 mn | 8.3% |
| UV-C and other physical | 20.0% | 25.7% | USD 187 mn | 12.8% |
| Viral clearance studies | 26.0% | 26.8% | USD 243 mn | 10.3% |
By product
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Kits and reagents | 38.0% | 34.6% | USD 355 mn | 9.0% |
| Systems and equipment | 24.0% | 23.9% | USD 224 mn | 10.0% |
| Services | 38.0% | 41.5% | USD 355 mn | 11.0% |
By end user
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Biopharma | 62.0% | 59.2% | USD 580 mn | 9.5% |
| Contract organisations | 24.0% | 27.5% | USD 224 mn | 11.5% |
| Plasma and blood product makers | 14.0% | 13.4% | USD 131 mn | 9.5% |
By stage
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Upstream | 24.0% | 22.0% | USD 224 mn | 9.1% |
| Downstream | 52.0% | 52.0% | USD 486 mn | 10.0% |
| Fill-finish | 24.0% | 26.0% | USD 224 mn | 10.9% |
By biologic
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Monoclonal antibodies | 52.0% | 48.0% | USD 486 mn | 9.1% |
| Plasma derivatives | 24.0% | 22.0% | USD 224 mn | 9.1% |
| Vaccines | 14.0% | 16.0% | USD 131 mn | 11.5% |
| Gene therapy vectors | 10.0% | 14.0% | USD 94 mn | 13.8% |
Top 25 countries for virus inactivation by revenue
Countries are ranked by revenue earned from sales in the country, not by where the product is made. The ten largest hold 87.5% of 2026 revenue and the 25 countries below together hold 96.2%.
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| # | Country | Value 2026 | Share 2026 | Value 2036 | CAGR 2026-36 |
|---|---|---|---|---|---|
| 1 | United States | USD 355 mn | 38.0% | USD 875 mn | 9.4% |
| 2 | Germany | USD 94 mn | 10.0% | USD 221 mn | 9.0% |
| 3 | China | USD 75 mn | 8.0% | USD 264 mn | 13.5% |
| 4 | Switzerland | USD 56 mn | 6.0% | USD 138 mn | 9.4% |
| 5 | Japan | USD 47 mn | 5.0% | USD 99 mn | 7.8% |
| 6 | United Kingdom | USD 47 mn | 5.0% | USD 114 mn | 9.3% |
| 7 | South Korea | USD 47 mn | 5.0% | USD 143 mn | 11.8% |
| 8 | France | USD 37 mn | 4.0% | USD 87 mn | 8.8% |
| 9 | Ireland | USD 33 mn | 3.5% | USD 80 mn | 9.3% |
| 10 | India | USD 28 mn | 3.0% | USD 99 mn | 13.5% |
| 11 | Netherlands | USD 18 mn | 1.9% | USD 45 mn | 9.4% |
| 12 | Spain | USD 11 mn | 1.2% | USD 27 mn | 9.4% |
| 13 | Canada | USD 8.0 mn | 0.8% | USD 20 mn | 9.5% |
| 14 | Italy | USD 6.5 mn | 0.7% | USD 16 mn | 9.3% |
| 15 | Belgium | USD 5.4 mn | 0.6% | USD 13 mn | 9.4% |
| 16 | Denmark | USD 4.8 mn | 0.5% | USD 12 mn | 9.3% |
| 17 | Sweden | USD 4.2 mn | 0.5% | USD 10 mn | 9.5% |
| 18 | Australia | USD 3.8 mn | 0.4% | USD 9.5 mn | 9.4% |
| 19 | Singapore | USD 3.5 mn | 0.4% | USD 12 mn | 13.6% |
| 20 | Taiwan | USD 3.3 mn | 0.3% | USD 8.0 mn | 9.3% |
| 21 | Israel | USD 3.0 mn | 0.3% | USD 11 mn | 13.6% |
| 22 | Austria | USD 2.8 mn | 0.3% | USD 7.0 mn | 9.6% |
| 23 | Brazil | USD 2.6 mn | 0.3% | USD 9.2 mn | 13.4% |
| 24 | Mexico | USD 2.5 mn | 0.3% | USD 8.7 mn | 13.2% |
| 25 | Turkey | USD 2.4 mn | 0.3% | USD 8.5 mn | 13.3% |
| Rest of world | USD 35 mn | 3.8% | USD 87 mn | 9.5% |
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
Competitive landscape
Group 1: Global leaders
- Merck KGaA
- Sartorius
- Cytiva
- Charles River Laboratories
- Pall Corporation
Group 2: Regional and specialist players
- Asahi Kasei Bioprocess
- Eurofins
- WuXi Biologics
- ViruSure
- Texcell
- SGS
- KBI Biopharma
- Lonza
- Cerus
- Macopharma
Group 3: Emerging and niche players
- Cobetter Filtration
- Vironova BioAnalytical
Research methodology
Every figure on this page comes from the research framework that we apply to all of the markets we cover. The 2025 base for the virus inactivation market is built from the volume sold and the price that buyers pay, and is cross-checked against the size of the wider industry the market belongs to. Where a market can be sized in more than one way, the routes are compared before a figure is set.
The forecast runs year by year from the 2025 base to 2036. Growth in each year reflects demand from the industries that buy the product, adoption of new technology, pricing, regulation and replacement cycles. Volume and price are modelled together, so revenue in each year equals volume multiplied by average price. The 2026 to 2036 compound annual growth rate of 10.0% is calculated from the resulting values.
The market is divided by method, by product, by end user, by stage, by biologic. The 25 largest countries are ranked by revenue earned from sales to buyers in each country, not by where the product is made. Segment values and country values add up to the market total in every year, and every report is checked for consistency before it is published.
Companies are placed in three groups: global leaders, regional and specialist players, and emerging and niche players. The groups describe how companies compete in the market. They are not a ranking and they are not market shares.
Our analysts also carry out primary research. Customized reports add interviews with key opinion leaders, such as senior executives, technical specialists and buyers, to test the assumptions behind the numbers for the question being asked.
Frequently asked questions
How big is the virus inactivation market?
The global virus inactivation market is estimated at USD 850 mn in 2025 and USD 935 mn in 2026.
How fast will the virus inactivation market grow?
It is forecast to reach USD 2.4 bn by 2036, a compound annual growth rate of 10.0% from 2026, an increase of USD 1.5 bn.
Which country is the largest market for virus inactivation?
United States is the largest market by revenue at USD 355 mn in 2026, 38.0% of the global total. The three largest countries together hold 56.0%.
Which country is growing fastest?
Among the ten largest markets, India is growing fastest at 13.5% a year from 2026 to 2036.
Which virus inactivation segment is largest?
In the by method split, Low pH hold is the largest segment with 30.0% of 2026 revenue.
Who are the leading virus inactivation companies?
Global leaders include Merck KGaA, Sartorius, Cytiva, Charles River Laboratories.
Need the full report?
Request a sample to see the structure, tables and country detail.
Request a free sampleRelated markets in Healthcare
- Early Pulmonary Embolism Thrombectomy DeviceUSD 935 mn · 12.0% CAGR
- Radiotherapy Positioning DevicesUSD 933 mn · 5.8% CAGR
- Epilepsy Monitoring DevicesUSD 942 mn · 7.5% CAGR
- Robotic Catheterization SystemsUSD 944 mn · 15.0% CAGR
- Glioblastoma Treatment DrugsUSD 945 mn · 5.5% CAGR
- Peptide Receptor Radionuclide Therapy (PRRT)USD 913 mn · 8.0% CAGR
- Biosafety CabinetUSD 958 mn · 7.0% CAGR
- Vaporized Hydrogen Peroxide Sterilization SystemUSD 905 mn · 7.0% CAGR